Release Date: 14-Feb-2023
One of Roche's most recent drugs, Lunsumio, has been approved for the treatment of relapsed or refractory follicular lymphoma. It is a first-in-class bispecific antibody that was approved in 2022 for the indication, and sales of it increased significantly between quarters. Sales have been decent for a new drug. Roche announced Lunsumio sales of CHF 1 Million (US$ 1.08 Million) and 2 Million (US$ 2.16 Million) in the third and fourth quarters of 2022, respectively. It is projected that sales will increase even more as it is approved for use in more subgroups of the follicular lymphoma patient population. With the potential to deliver prolonged remissions and a longer gap between treatments after the initial therapy, the drug is a novel type of immunotherapy with a fixed-duration treatment option. This is believed to be a major factor in its global uptake. By developing and commercializing Lunsumio, Roche hopes to shift the way of the treatment of follicular lymphoma, a kind of blood cancer that is presently thought to be incurable.
Download Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028: